Home Companies Catalysts Deep Dives
Epclusa sofosbuvir/velpatasvir APPROVED
Drug Profile
ModalitySmall molecule
RoutePO
Therapy AreaInfectious Disease
Launch2016-06-28
US LOE2029-06-28
Peak Sales Est$2000M
Formulations[{"id":"epclusa-tablet","route":"PO","setting":"PATIENT_SELF","frequency":"Once daily x 12 weeks","i
Companies
GILD (ORIGINATOR)100%
Mechanism: NS5A/NS5B inhibitor
Expert: Pan-genotypic inhibition of HCV NS5A and NS5B polymerase.
Everyday: Blocks proteins HCV needs to replicate.
Targets: ["NS5A","NS5B"]
Revenue History
PeriodRevenue ($M)
2023$1,521M
2024$1,612M
Programs (1)
IndicationStageKey StudyRegional Status
Chronic HCVAPPROVEDASTRAL-1/2/3[{"stage":"APPROVED","region":"US","approval_date":"2016-06-28"}]
Notes
Pan-genotypic HCV cure. Market leader in HCV.
Data from Supabase · Updated 2026-03-24